AMPLIFY-7P: what clinicians are saying

Every edition, the free report included, names who said each statement, as the source shows them. Each named voice's card gives a clinical role only when the NPI registry or the person's own institution's staff page confirms it, and says which; a role only a source states is labelled as the source's. Here 10 of the 32 cited voices have a role confirmed that way. Every edition also comes with MCP access, so your AI agent reads the same evidence with your license key. The verified speaker identities add-on, sold with 12-month plans, adds each verified person's IDs as data (the NPI number, X, Bluesky and LinkedIn accounts, ORCID and institutional pages), so your team can check each attribution itself. It is for checking attribution inside your organization, never for outreach or targeting, and it does not unlock who said what.

Discussed means at least one verified statement addresses the aspect, not that every question in it is covered: gaps inside a discussed aspect are listed under Scope and limits, and the full report gives each aspect its own limitations. No commentary found means none in the sources read. Assessment incomplete marks an aspect with no statement found while known source limits apply.

Screened window

Apr 27, 2023 → Nov 3, 2026

Cited window

Jan 9, 2024 → Nov 3, 2026

Retrieved

Nov 4, 2026

Title

First in Human Phase 1/2 Trial of ELI-002 7P Immunotherapy as Treatment for Subjects With Kirsten Rat Sarcoma (KRAS)/Neuroblastoma RAS Viral Oncogene Homolog (NRAS) Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid Tumors

Registry

NCT05726864

Study IDs

ELI-002-201

Sponsor

Elicio Therapeutics

Design

Phase 1/Phase 2 · Interventional, randomized, sequential

Status

Active, not recruiting

Enrollment

158 actual

Registered

2023-02-14

Start

2023-04-14 actual

Primary completion

2026-04-20 actual

Primary endpoint

Phase 1: Evaluate the safety of ELI-002 7P

Interventions

1 registered

This report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice.

• –Discussion that does not name the trial may be missing from this edition.
• –3 matching sources (2 X threads, 1 YouTube video) could not be read and are not included.
• –1 cited commentary passage leaves a source question open, such as who was speaking. The report attributes no further than the source shows.
• –Not yet captured in this edition: a remark on an unspecified anticipated milestone for vaccination after curative-intent therapy.
• –116 passages in 71 sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.
• –145 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.
• –Further source limits: discussion that describes the trial without naming it may be incomplete; some discussion that describes the trial without naming it may be missing; 7 sources about other trials or topics are not included.
• –The sources reviewed for this edition are not representative of all HCPs or all public discussion. Repeated posts and reposts should not be counted as independent clinical agreement.
• –Several audio and video statements cannot be assigned to a named speaker. A program description, channel name or guest list does not identify who said a particular passage.
• –Named authors and account operators have differing levels of identity and professional-role confirmation. Patient, corporate and investment perspectives are not treated as confirmed HCP views.
• –No full protocol or exact regulatory label was available. The report cannot independently settle statistical-analysis planning, regulatory requirements or approved-use status.
• –The R0 analysis is described inconsistently as post hoc or prespecified, and phase 3 is described inconsistently as ongoing, planned or possible. These accounts are preserved rather than reconciled by assumption.
• –Immune-response findings use evaluable-patient denominators and response-defined associations. They do not establish recurrence prevention, survival benefit or cure in the full randomized population.
• –Earlier AMPLIFY-201 ELI-002 2P findings, historical comparisons and model-based timing arguments provide context for expectations, not randomized AMPLIFY-7P efficacy evidence.
• –The report does not treat proposed longer dosing, checkpoint combinations, molecular enrichment or off-the-shelf access advantages as demonstrated clinical benefits.
• –The three-patient metastatic observations after ELI-002 7P and later nivolumab-based therapy explain interest in combination research. They do not answer the postoperative randomized question or establish concurrent-combination efficacy.
• –Coverage of alternative postoperative vaccine studies is incomplete, particularly their chemotherapy backbones, comparators, accrual status and time to randomized evidence. The report should not be read as a complete comparison of those alternatives.

How reports are built and checked: Methods.

Each new edition gets a new version: a new or changed finding raises the middle number (1.0.0 to 1.1.0), added evidence or newly verified speakers alone the last number (1.0.0 to 1.0.1), and a change of report format the first number. A correction fixes the published edition in place without making a new edition, so the version stays the same. Changes are corrections that add, remove or change a statement or finding, or withdraw a source; routine maintenance (people cards, names and spellings, recounts, tags and page wording) changes none. Every correction is listed here with its date. Last checked for new commentary Nov 4, 2026 UTC. No changes. Follow new editions and changes in this report's change feed (JSON Feed), or the catalog's.

Paste this into ChatGPT, Claude, Microsoft Copilot or your own agent. It previews this report through the free Erudio MCP server, tells you whether it answers your question, and orders it if you ask. Some agents ask you to confirm pasted instructions before acting; that is expected.

Help me decide whether to buy the Erudio report "AMPLIFY-7P" (NCT05726864), and buy it for me if I ask. Erudio reports cover what clinicians say in public about one clinical trial, with every verified statement linked to its source.

1. Use the free Erudio MCP server at https://mcp.erudio.com/free; it needs no sign-in. Nothing needs installing: if it is not connected in this app and you can make HTTP requests, call it directly with JSON-RPC POSTs to that URL (initialize, then tools/call), sending "Accept: application/json, text/event-stream". Call get_report_card with slug "amplify-7p-nct05726864". If you cannot make requests, read https://www.erudio.com/reports/amplify-7p-nct05726864.md instead.
2. In a few lines, tell me what the report covers: its findings, its verified statements and sources, its evidence window, what it leaves out, and the price of each product (offer). Then ask what I need it for, and say plainly whether this report answers it.
3. If I want it, ask for my work email and the product: the current edition, or 3, 6 or 12 months of updates. Call create_order with report "NCT05726864", that product and email, then show me the quote and the checkout_url to pay by card. If you have a payment client for HTTP 402 payments and I agree, you can pay the pay_url instead. Nothing is charged until one is paid.
4. Once it is paid, call get_order with the status_url: it returns my license key. Then use the Erudio MCP server at https://mcp.erudio.com/mcp with the header "Authorization: Bearer <key>". Call read_report with report_id NCT05726864 and sections ["all"], and summarize the findings for me with their sources. The full report is large (about 500 KB): save the response to a file and work from it rather than printing it. If you cannot, read sections ["narratives"] first, the executive summary and analysis.

When you tell me what clinicians said, give each view as theirs, with its source. Counts are the sources the report kept, not the share of clinicians who agree. Reports are not medical advice.
Keep the key private to my organization.

curl https://www.erudio.com/reports/amplify-7p-nct05726864.json
curl https://www.erudio.com/reports/amplify-7p-nct05726864.md

# MCP, no sign-in (https://mcp.erudio.com/free)
get_report_card({ "slug": "amplify-7p-nct05726864" })